Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

ASXL1 Is a Key Regulator for Erythroid Development and Asxl1 Loss Impairs Erythropoiesis In Vivo

Shohei Yamamoto, MD PhD, Hui Shi, MD PhD, Shi Chen, MD PhD, Peng Zhang, PhD, Yuan Zhou, PhD, Mingjiang Xu, MD PhD, Feng-Chun Yang, MD PhD

Blood (2015) 126 (23): 3644.

https://doi.org/10.1182/blood.V126.23.3644.3644

Published: 2015

Journal Articles

Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells

Maria Rosaria Ricciardi, PhD, Roberto Licchetta, Paola Bergamo, Stefano Iacovelli, Andrea Miele, Maria Teresa Petrucci, MD, Michele Milella, MD, Claudio Pisano, PhD, Agostino Tafuri, MD

Blood (2010) 116 (21): 4946.

https://doi.org/10.1182/blood.V116.21.4946.4946

Published: 2010

Journal Articles

Inactivation of Pathogens in Red Blood Cells by a Modified Treatment Process Utilizing S-303 and Glutathione.

L. Sawyer, R. Mababangloob, N. Patel, J. Kinsey, A. Sampson-Johannes, D. Hanson

Blood (2006) 108 (11): 4144.

https://doi.org/10.1182/blood.V108.11.4144.4144

Published: 2006

Journal Articles

A Modified Process for Preparation of Pathogen Inactivated RBC Using S-303 in Multiple Additive Solutions Maintains RBC Function and Reduces Immunologic Activity.

A.C. Erickson, V.A. Lee, M.A. Schott, G.M. Castro, T. Peterson, A. North

Blood (2006) 108 (11): 943.

https://doi.org/10.1182/blood.V108.11.943.943

Published: 2006

Journal Articles

Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).

Maureen G. Conlan, MD, George Garratty, PhD, FRCPath, Grace Castro, Anna Erickson, Mary Ann Schott, Pat Arndt, David Cook, PhD, Laurence Corash, MD, Adonis Stassinopoulos, PhD

Blood (2005) 106 (11): 430.

https://doi.org/10.1182/blood.V106.11.430.430

Published: 2005

NARROW

ASXL1 Is a Key Regulator for Erythroid Development and Asxl1 Loss Impairs Erythropoiesis In Vivo

Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells

Inactivation of Pathogens in Red Blood Cells by a Modified Treatment Process Utilizing S-303 and Glutathione.

A Modified Process for Preparation of Pathogen Inactivated RBC Using S-303 in Multiple Additive Solutions Maintains RBC Function and Reduces Immunologic Activity.

Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).

Email alerts

ASH Publications

American Society of Hematology

ASXL1 Is a Key Regulator for Erythroid Development and Asxl1 Loss Impairs Erythropoiesis In Vivo

Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells

Inactivation of Pathogens in Red Blood Cells by a Modified Treatment Process Utilizing S-303 and Glutathione.

A Modified Process for Preparation of Pathogen Inactivated RBC Using S-303 in Multiple Additive Solutions Maintains RBC Function and Reduces Immunologic Activity.

Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only